Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

ng statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 3 studies and/or our development of clevudine, the risk that the registration clinical trials of clevudine will not be successful or will not provide meaningful data, the risk that the on- going or anticipated clinical trials for any one or more of our product candidates will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Reportlinker.com announces that a new market ... The Market for Medical Devices in EMEA  ... Middle Eastern and African markets represent significant opportunity ... its coverage, this study: The Market for Medical ... device markets and estimates markets for specific device ...
(Date:8/20/2014)... Reportlinker.com announces that a new market ... Global Patient Scales Industry ... the worldwide markets for Patient Scales in US$ ... Infant & Baby Scales, Chair Scales, and Under ... for the US, Canada, Japan, Europe, Asia-Pacific, Latin ...
(Date:8/20/2014)... -- Glenmark Pharmaceuticals S.A. (GPSA), a ... (GPL), announces the discovery and initiation of IND ... GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 ... Research Centre located in La Chaux-de-Fonds, ... Glenmark,s innovative BEAT antibody technology platform which facilitates ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
(Date:8/20/2014)... no secret that millions of Americans are struggling with ... Abuse, nearly 24 million Americans are using some form ... fact that the total number of users has increased ... struggle with substance abuse often feel there may never ... has released updated lists of substance abuse resources ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... -- Taking the widely used antibiotic clarithromycin ... causes, a new study suggests. Because millions of ... urgent confirmation, said the Danish researchers behind the study. ... and that guidelines for the use of the drug ... One heart expert wasn,t surprised by the finding, ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 If ... has found a cure for it. With extensive research on ... provider named ‘MetroMD’ claims to have perfected the art of ... you a brand new younger look with their revolutionary anti-aging ... secrets of the 21st century fountain of youth, the MD ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2
... may indicate underlying disease, study finds , , FRIDAY, Aug. 8 ... play a pivotal role in increasing an older American,s risk ... a new report says. , Levels of adiponectin increase in ... the cardiovascular health of older people, according to the new ...
... Alaska The University of Alaska Fairbanks campus will be ... 12-14, 2008. , The biennial conference is organized in ... Arctic Region and brings together international participants to address ... host to the 2008 conference. , More than150 guests ...
... Delivers Cheer, Medication and Equipment to Young Patients and Helps ... Raise Money for Make-A-Wish ... general,availability of its train-themed "JR" autonomous mobile robot to children,s,hospitals ... the,national Make-A-Wish Foundation for each JR TUG that is deployed. ...
... 1-inch cut behind uterus and into woman,s body cavity ... they say may be the first operation of its ... Hospital/Columbia University Medical Center removed a woman,s gallbladder without ... as part of an ongoing clinical research trial, involved ...
... EDT, Thursday, ... August 14, PRINCETON, ... advanced wound care products,announced plans to release its second quarter 2008 results ... the Company will,hold a conference call that same day to discuss the ...
... Inc. (NYSE: HGR ) is pleased to ... Hanger Orthopedic Group, Inc. to "positive",from "stable." Moody,s ... "We are pleased with the outlook change ... the last ten quarters," remarked George McHenry,Hanger,s Chief ...
Cached Medicine News:Health News:Fat Cell Protein Boosts Heart Attack Risk in Elderly 2Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:Derma Sciences Conference Call Advisory 2
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: